U.S. and Switzerland reach trade deal to lower tariffs to 15%

The U.S. and Switzerland have finalized a trade deal, reducing duties on Swiss imports from 39% to 15%, aligning them with EU rates. As part of the agreement, Swiss companies committed to investing $200 billion in the U.S. by 2028, focusing on manufacturing sectors like pharmaceuticals and gold smelting, which U.S. Trade Representative Jamieson Greer stated will help address the trade deficit and boost American manufacturing. This development, which follows previous tariffs that negatively impacted Swiss economic growth, stabilized bilateral trade relations and led to a 0.4% appreciation of the Swiss franc against the dollar.

Analysis

The U.S. and Switzerland have finalized a trade agreement, reducing duties on Swiss imports from 39% to 15%, matching rates for EU goods. This deal includes a significant commitment from Swiss companies to invest $200 billion in the U.S. by 2028, targeting manufacturing sectors like pharmaceuticals and gold smelting. The Swiss franc appreciated 0.4% against the U.S. dollar post-announcement, signaling immediate positive market reception.

U.S. Trade Representative Jamieson Greer emphasized the deal's aim to address the trade deficit and bolster American manufacturing, citing specific pledges such as Roche's $50 billion investment. For Switzerland, an export-driven economy, the agreement is crucial for stabilizing bilateral trade relations and is expected to positively impact its economy, which previously saw its 2026 growth forecast cut due to the "heavy burden" of the higher tariffs.

This agreement strategically manages trade imbalances while fostering foreign direct investment in critical U.S. industries. The $200 billion investment commitment, particularly in high-value sectors, signifies a shift towards collaborative economic engagement rather than solely punitive tariffs. Retaining a 15% tariff rate indicates a continued focus on trade balance while promoting domestic production and supply chain resilience.

Key Decisions for Investors

• Evaluate Swiss companies with significant U.S. export exposure, particularly in pharmaceuticals and precious metals, for improved market access and operational stability
• Consider U.S. manufacturing and related supply chain companies as potential beneficiaries of the $200 billion Swiss investment
• Monitor the Swiss franc for continued strength against the U.S. dollar, reflecting reduced economic uncertainty and stabilized trade relations
• Assess this agreement as a potential template for future U.S. trade policy, emphasizing investment commitments to address trade imbalances